Australia's most trusted
source of pharma news
Posted 24 March 2026 PM
Gilead Sciences is adding to the $4 million it has awarded to support innovative, local, practice-focused research that seeks to improve patient outcomes in HIV, chronic viral hepatitis, COVID-19 and haematological malignancies.
Australian researchers, healthcare professionals and multidisciplinary teams undertaking projects aligned with the program’s priority disease areas can apply for the 2027 Gilead Australia Medical Fellowships, which prioritise real world clinical or community-based projects, initiatives that enhance best practice, and research addressing unmet needs.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.